WebThe purpose phase I of this trial is to characterize safety and tolerability and determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of MAK683. … WebMAK683 ( N - ( (5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8- (2-methylpyridin-3-yl)- [1,2,4]triazolo [4,3- c ]pyrimidin-5-amine) is a potent and orally bioavailable EED inhibitor …
MAK683 on Diffuse Large B-cell Lymphoma - Clinical Trials …
WebApr 14, 2024 · Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies. J Med Chem. … WebSep 21, 2024 · Clinical trials with numerous CMP inhibitors are also currently in progress to evaluate the therapeutic potential of epigenetic inhibitors. In this review, we aim to provide a summary of genetic mutations in epigenetic genes and a review of CMP inhibitors suitable for preclinical studies or currently in clinical trials. ... MAK683, is currently ... meet in youth love in foods episode dorama
Home - ClinicalTrials.gov
WebMar 23, 2024 · Overexpression and somatic heterozygous mutations of EZH2, the catalytic subunit of polycomb repressive complex 2 (PRC2), are associated with several tumor types. EZH2 inhibitor, EPZ-6438 (tazemetostat), demonstrated clinical efficacy in patients with acceptable safety profile as monotherapy. EED, a … WebSep 2, 2016 · Detailed Description. The purpose phase I of this trial is to characterize safety and tolerability and determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of MAK683. The purpose of the phase II of this trial is to evaluate the anti-tumor activity of MAK683. Phase II part will not be opened. WebNov 23, 2024 · MAK683 is a specific oral inhibitor that impairs EED binding to H3K27me3. This is a Phase I/II study of MAK683 in adult patients with advanced malignancies for … meet in youth love in foodsseriesflix